Two surgical fellowships

Article

The training component of the Mercy Vision programme, onboard the world's largest non-governmental hospital ship, is to receive $50,000 from the Alcon Foundation.

The training component of the Mercy Vision programme, onboard the world's largest non-governmental hospital ship, is to receive $50,000 from the Alcon Foundation.

Funding covers expenses for the Mercy Ships Alcon Fellowship - two three-month surgical fellowships for expatriate or national West African surgeons onboard the hospital ship in Cotonou, Benin, West Africa. The fellowship will offer training in advanced cataract techniques and will complement additional training done with community eye workers and local eye surgeons to help build capacity during the ship's 10-month port visit.

According to Dr. Glenn Strauss, chief of Ophthalmology Service and Senior VP of Strategic Health Care for Mercy Ships, patients in Africa often develop more dense and severe cataracts due to the frequency of eye trauma, the intensity of the sun's rays along the equator, nutritional issues, and lack of access to ophthalmic intervention. Surgeons need to understand all of the techniques available to them and how they can provide the most affordable quality care in the areas they are working in.

“We believe that teaching these techniques contributes to a sustainable solution to eye care needs in Africa because they are suited to local patients,” said Strauss, who began training the first fellowship grantee from Gabon this month. The fellowship training will also emphasize whole-patient care concepts, developing the trainees' skills to meet the variety of challenges they will experience as future leaders in eye care.

Alcon has partnered witth Mercy Ships since the charity's inception 30 years ago. Since 1997 Alcon has donated more than $5.6 million worth of equipment, supplies, and pharmaceuticals to support Mercy Ships efforts to address preventable blindness.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.